COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

11.57 -0.62 (-5.09%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2

...

27 28 29 30 31 32 33 34 Next >

1 Recent Healthcare IPO to Put on Your Radar ↗

September 24, 2021

Here's a pharmaceutical company that could have an incredibly bright future.

Via The Motley Fool

Topics Initial Public Offering

Is Ketamine A Psychedelic? Depends On Who You Ask ↗

September 22, 2021

Ketamine, an FDA-approved anesthetic drug, has recently become the star of the psychedelic medicine movement. As p...

Via Benzinga

Senate Bill Decriminalizing Psychedelics Could Help Reverse Some “War on Drugs” Impacts

September 22, 2021

Via FinancialNewsMedia

The Three Psychedelics ETFs: Which Is The Best Fit For Your Portfolio? ↗

September 21, 2021

We compare and contrast the three psychedelic drug ETFs and assess which investor needs each addresses.

Via Talk Markets

Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial ↗

September 20, 2021

AdvisorShares Launches First NYSE-listed Actively-managed Psychedelics ETF On Thursday, AdvisorShares

Via Benzinga

Analyzing Compass Pathways's Unusual Options Activity ↗

August 11, 2021

On Wednesday, shares of Compass Pathways (NASDAQ:CMPS) sa...

Via Benzinga

Analyzing Compass Pathways's Unusual Options Activity ↗

August 10, 2021

Shares of Compass Pathways (NASDAQ:CMPS) saw some unusual...

Via Benzinga

Which Psychedelic Stock ETF Is Right For You? ↗

September 18, 2021

This week the AdvisorShares Psychedelics ETF began trading on the NYSE Arca. Here we compare the make-up of the now 3 psychedelic stock ETFs and two tracking indexes.

Via Talk Markets

Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0 ↗

September 15, 2021

Psychedelics biotech company Compass Pathways (NASDAQ:CMPS...

Via Benzinga

Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry? ↗

September 09, 2021

By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate...

Via Benzinga

National Suicide Prevention Week Shines Light on Psychedelic Treatments

September 09, 2021

Via FinancialNewsMedia

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 08, 2021

Gainers Cardiff Oncology (NASDAQ:

Via Benzinga

3 Biotech Stocks Wall Street Expects to Double Soon ↗

September 07, 2021

All three stocks on this list can more than double your money according to investment bank analysts who cover them.

Via The Motley Fool

Psychedelic Drug Industry Report Card For 2021 ↗

September 01, 2021

In assessing the psychedelic drug industry, a primary focus for investors is drug development.

Via Talk Markets

Magic Mushroom Drug Stock Performances YTD ↗

August 29, 2021

Of the 35 companies involved in clinical stage research of psychedelic substances, 20 are researching the benefits of psilocybin, the primary psychoactive ingredient in “magic mushrooms”.

Via Talk Markets

Braxia Scientific Launches Broad Criteria Trial On Psilocybin For Depression ↗

August 27, 2021

Braxia Scientific Corp. (CSE:BRAX) (OTC:

Via Benzinga

Open-Minded? Buy This Game-Changing Psychedelics Stock Now ↗

August 26, 2021

Excellent investing opportunities frequently seem outlandish.

Via The Motley Fool

Topics Supply Chain

Psychedelic Drug Patents: All Patents Are Not Created Equal ↗

August 20, 2021

With many drug patenting opportunities in the emerging psychedelic drug industry, investors need to get up-to-speed on the different types of patents available -- and their strengths and weaknesses.

Via Talk Markets

Topics Intellectual Property

3 Disruptive Mental Health Stocks to Consider Buying Before They're Huge ↗

August 14, 2021

They're the first pioneers in exciting new markets.

Via The Motley Fool

Compass Pathways Q2 Financials: Net Profit Down -38%; Stock Down -59% YTD ↗

August 12, 2021

COMPASS Pathways plc reported its financial results for the Q2 ending June 30th, 2021, today, and gave an update on recent progress across its business.

Via Talk Markets

Atai Life Sciences To Research Potent Psychedelic Herb Salvia Divinorum Through Its New Subsidiary ↗

August 12, 2021

Atai Life Sciences (NASDAQ:ATAI) has announced the launch ...

Via Benzinga

COMPASS Pathways plc (CMPS) Q2 2021 Earnings Call Transcript ↗

August 11, 2021

CMPS earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Which Psychedelic Drug Has The Most Commercial Potential? ↗

August 10, 2021

As the Mental Health Crisis has become a mental health pandemic, clinical research on psychedelic drugs is showing that these substances are the best – and only – option to address this crisis.

Via Talk Markets

Cybin Becomes First Psychedelics Company On The NYSE: CEO Explains Everything You Need To Know ↗

August 05, 2021

Cybin (NYSE:CYBN), a biotech company in the psychedelics spa...

Via Benzinga

Growing Psychedelic Interest Will Help Push Compass Pathways Stock Up 3X By 2022 ↗

August 04, 2021

Psychedelic stock headwinds are improving, and since Compass is at the forefront of psychedelic therapy, look for CMPS stock to take off soon.

Via InvestorPlace

Another Psychedelic Stock Debuts, As This One Sets Up In A Base ↗

July 29, 2021

Field Trip Health dipped in its first day on the Nasdaq, making it the latest psychedelics company to hit a big U.S. exchange.

Via Investor's Business Daily

Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To "Psychedelics Renaissance" ↗

July 23, 2021

Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector. On Friday,

Via Benzinga

Post-COVID Investment Mega-Opportunity: Mental Health And Psychedelic Drug Stocks ↗

July 15, 2021

After governments have obsessed for the past 18 months about COVID-19, they are now forced to confront a much larger pandemic: the Mental Health Pandemic. This enormous crisis is also a huge investing...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021 ↗

July 13, 2021

Upgrades For Royal Dutch Shell PLC (NYSE:RDS), Bar...

Via Benzinga

Psychedelic Decriminalization Creating Market Opportunities

July 12, 2021

Via FinancialNewsMedia

Topics Cannabis Law Enforcement

< Previous 1 2

...

27 28 29 30 31 32 33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.